Neratinib Shrank Brain Mets in Half of HER2+ Breast Cancer Patients

This video examines results of a phase II trial that studied the combination of neratinib plus capecitabine for the treatment of recurrent brain metastases in HER2-positive breast cancer patients.

Source: CancerNetwork - June 6, 2017 Category: Cancer & Oncology Authors: Rachel A. Freedman, MD, MPH Tags: Conferences/ASCO Breast Cancer HER2-Positive Breast Cancer News Videos Breast Cancer Source Type: news